s PhD=in Econ at MIT, and remains a good friend: Mark McClellen, who is interest=d in this stuff and remains quite influential in DC, I think). But the reas=n for rambling about the FDA and placebo effects is the following. T=is morning I just had an exchange of emails with the CEO of EB, whom I4>=804,ve known